Clin2
NCT07356713Possibly a fitRecruiting

Finding the right dose of EXL-111 for healthy volunteers

Allergic Disease

Treatments studied

Part of Immune system & allergy clinical trials.

This trial tests a new drug called EXL-111 in healthy people to find the safest and best dose for future studies. It may help people with allergies if the drug proves effective.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
70 people
Ages
18 years to 55 years
Study type
Interventional

Who can take part

  • You are between 18 and 55 years old
  • You weigh between 99 and 264 pounds with a body mass index between 18 and 32
  • Your blood level of an antibody related to allergies (called IgE) is in a specific range (30 to 300 IU/mL)
  • You do not smoke or use tobacco, and haven't for the past 2 months (very light use may be okay)
  • You are willing to follow study rules and sign a consent form

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06828393Recruiting· Phase 1
Study of S-1117 in healthy volunteers

This study tests a new medicine called S-1117 in healthy volunteers to see how safe it is and how it works in the body. It is a first-in-human trial that helps researchers learn about the medication before testing it in people with a condition.

Adelaide, South Australia
NCT07701954Recruiting· Phase 1
Testing a new drug for people with allergies and high IgE

This early-phase trial tests a new medication, LCA-0061, in healthy people with high IgE levels (a sign of allergies). Part B specifically includes those with a peanut allergy. The study aims to see how safe the drug is and how the body processes it.

Mississauga, Ontario
NCT07038746Recruiting· Phase 1
Inhaled epinephrine for severe allergic reactions during tests or treatment

This trial tests if inhaled epinephrine can safely treat moderate to severe allergic reactions (grade 2 or higher) that can happen during allergy skin tests, oral food or drug challenges, or allergy shots. It is for people who have had such reactions in the past or are at risk and are planning to undergo one of these procedures.

Richmond, British Columbia
NCT06934200Recruiting· Phase 2
Xolair for food allergy in people with high IgE

This study tests if omalizumab (Xolair), an injectable medicine that blocks allergy antibodies, can help people with food allergies tolerate small amounts of their trigger foods. It's for people with high total IgE levels who were not eligible for a related study.

Baltimore, Maryland
NCT07042113Not yet recruiting· Phase 1
Testing a different version of an experimental drug in healthy adults

This study compares two versions of an experimental drug called 611 to see how they work in the body. It's for healthy volunteers to help find the best formulation for future treatments.

Wenzhou, Zhejiangsheng
NCT06999720Recruiting· Phase 1
Study of an experimental drug in healthy volunteers

This trial is testing a new drug called HX15001 in healthy adults to see how safe it is and how the body processes it. It may help researchers decide if the drug can be tested in people with a specific condition in the future.

Herston, Queensland

Hear when a new Allergic Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.